Biswas S - Search Results

1

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody.

Lennartz F, Brod F, Dabbs R, Miura K, Mekhaiel D, Marini A, Jore MM, Søgaard MM, Jørgensen T, de Jongh WA, Sauerwein RW, Long CA, Biswas S, Higgins MK. Lennartz F, et al. Among authors: biswas s. Nat Commun. 2018 Sep 20;9(1):3822. doi: 10.1038/s41467-018-06340-9. Nat Commun. 2018. PMID: 30237518 Free PMC article.

2

Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.

Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV. Draper SJ, et al. Among authors: biswas s. Cell Host Microbe. 2009 Jan 22;5(1):95-105. doi: 10.1016/j.chom.2008.12.004. Cell Host Microbe. 2009. PMID: 19154991 Free PMC article.

3

New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.

Goodman AL, Epp C, Moss D, Holder AA, Wilson JM, Gao GP, Long CA, Remarque EJ, Thomas AW, Ammendola V, Colloca S, Dicks MD, Biswas S, Seibel D, van Duivenvoorde LM, Gilbert SC, Hill AV, Draper SJ. Goodman AL, et al. Among authors: biswas s. Infect Immun. 2010 Nov;78(11):4601-12. doi: 10.1128/IAI.00315-10. Epub 2010 Aug 16. Infect Immun. 2010. PMID: 20713623 Free PMC article.

4

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.

Biswas S, Dicks MD, Long CA, Remarque EJ, Siani L, Colloca S, Cottingham MG, Holder AA, Gilbert SC, Hill AV, Draper SJ. Biswas S, et al. PLoS One. 2011;6(6):e20977. doi: 10.1371/journal.pone.0020977. Epub 2011 Jun 16. PLoS One. 2011. PMID: 21698193 Free PMC article.

5

The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody.

Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, Wyllie DH, Crosnier C, Miura K, Wright GJ, Long CA, Osier FH, Marsh K, Turner AV, Hill AV, Draper SJ. Douglas AD, et al. Among authors: biswas s. Nat Commun. 2011 Dec 20;2:601. doi: 10.1038/ncomms1615. Nat Commun. 2011. PMID: 22186897 Free PMC article.

6

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.

Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ. Sheehy SH, et al. Among authors: biswas s. PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21. PLoS One. 2012. PMID: 22363582 Free PMC article. Clinical Trial.

7

T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.

Forbes EK, de Cassan SC, Llewellyn D, Biswas S, Goodman AL, Cottingham MG, Long CA, Pleass RJ, Hill AV, Hill F, Draper SJ. Forbes EK, et al. Among authors: biswas s. PLoS One. 2012;7(9):e44943. doi: 10.1371/journal.pone.0044943. Epub 2012 Sep 12. PLoS One. 2012. PMID: 22984589 Free PMC article.

8

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.

Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ. Sheehy SH, et al. Among authors: biswas s. Mol Ther. 2012 Dec;20(12):2355-68. doi: 10.1038/mt.2012.223. Epub 2012 Oct 23. Mol Ther. 2012. PMID: 23089736 Free PMC article. Clinical Trial.

9

Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.

Elias SC, Collins KA, Halstead FD, Choudhary P, Bliss CM, Ewer KJ, Sheehy SH, Duncan CJ, Biswas S, Hill AV, Draper SJ. Elias SC, et al. Among authors: biswas s. J Immunol. 2013 Feb 1;190(3):1135-47. doi: 10.4049/jimmunol.1201455. Epub 2013 Jan 4. J Immunol. 2013. PMID: 23293353 Free PMC article. Clinical Trial.

10

The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.

Goodman AL, Forbes EK, Williams AR, Douglas AD, de Cassan SC, Bauza K, Biswas S, Dicks MD, Llewellyn D, Moore AC, Janse CJ, Franke-Fayard BM, Gilbert SC, Hill AV, Pleass RJ, Draper SJ. Goodman AL, et al. Among authors: biswas s. Sci Rep. 2013;3:1706. doi: 10.1038/srep01706. Sci Rep. 2013. PMID: 23609325 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,030 results

Search Page